{"date":"2026-05-31","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6576-2026-05-31-1323-10748p2","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-05-31","time":"13:23:36","subject":"亮丙瑞林注射乳劑新增停經前乳癌適應症上市許可申請獲中國國家藥品監督管理局（NMPA）受理進入實質審查","clause":"第10款","fact_date":"2026-05-31","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-05-31 13:23，「亮丙瑞林注射乳劑新增停經前乳癌適應症上市許可申請獲中國國家藥品監督管理局（NMPA）受理進入實質審查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}